Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: An open-label clinical study
Background: Negative symptoms and diminished cognitive ability are also considered as core features of schizophrenia. There are many studies in which negative symptoms and cognitive impairments are individually treated with atypical antipsychotic in comparison with either a placebo or a typical anti...
Main Authors: | Subodh Kumar, Suprakash Chaudhury |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2014-01-01
|
Series: | Industrial Psychiatry Journal |
Subjects: | |
Online Access: | http://www.industrialpsychiatry.org/article.asp?issn=0972-6748;year=2014;volume=23;issue=1;spage=27;epage=35;aulast=Kumar |
Similar Items
-
Amisulpride and olanzapine in Capgras Syndrome
by: G Sanghamitra, et al.
Published: (2017-01-01) -
The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study
by: Liang Y, et al.
Published: (2017-04-01) -
Effectiveness of amisulpride in Chinese patients with predominantly negative symptoms of schizophrenia: a subanalysis of the ESCAPE study
by: Liang Y, et al.
Published: (2017-06-01) -
Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis
by: Peng Men, et al.
Published: (2018-09-01) -
Olanzapine has better efficacy compared to risperidone for treatment of negative symptoms in schizophrenia
by: P N Suresh Kumar, et al.
Published: (2016-01-01)